ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

Professional Societies: ACCI Selects UPCI To Manage Operations; Elects New Officers

December 3, 1999

FDA Nearly Wrecks NCI Drug Distribution Program, Finally Agrees To New Guidelines

January 30, 1976

Cech To Step Down At HHMI In 2009.

April 18, 2008

New Funding Mechanisms – Cooperative Agreement, Consortium Grant – Proposed For Clinical Groups

April 6, 1979

UCSD Cancer Center Breaks Ground for New Building

November 15, 2002

NCI Plans Trials of Burzynski’s ‘Antineoplaston’; JAMA Report Says No Antitumor Activity In Tests

June 5, 1992